DECADRON W/ XYLOCAINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DECADRON W/ XYLOCAINE (DECADRON W/ XYLOCAINE).
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
| Metabolism | Dexamethasone is primarily metabolized by CYP3A4. Lidocaine is extensively metabolized by CYP1A2 and CYP3A4 to active metabolites (MEGX, GX). |
| Excretion | Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged). |
| Half-life | Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease). |
| Protein binding | Dexamethasone: 77%, primarily albumin. Lidocaine: 60-80%, alpha-1-acid glycoprotein. |
| Volume of Distribution | Dexamethasone: 0.8-1.0 L/kg (distributes widely). Lidocaine: 1.1-1.6 L/kg (increased in hepatic disease). |
| Bioavailability | Dexamethasone: Oral: 80-90%; IM: 100%. Lidocaine: Oral: <35% (first-pass); Epidural: 100%. |
| Onset of Action | Dexamethasone: IV: rapid (hours); IM: 1-2 hours. Lidocaine: Epidural: 5-15 min; Subcutaneous: 3-5 min. |
| Duration of Action | Dexamethasone: 24-72 hours (suppression of adrenal axis). Lidocaine: Epidural: 60-90 min; Subcutaneous: 30-60 min. |
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
| Dosage form | INJECTABLE |
| Renal impairment | Dexamethasone: No adjustment. Lidocaine: GFR <10 mL/min: reduce dose by 25-50% or avoid continuous infusion; monitor for toxicity. |
| Liver impairment | Dexamethasone: No adjustment. Lidocaine: Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 75%. |
| Pediatric use | Dexamethasone: 0.08-0.3 mg/kg/day oral/IV divided every 6-12h (max 16 mg/day). Lidocaine: 1-1.5 mg/kg IV bolus (max 100 mg), then 20-50 mcg/kg/min IV infusion; or local infiltration 4.5 mg/kg (max 300 mg) with epinephrine. |
| Geriatric use | Dexamethasone: Start at lowest adult dose; monitor for fluid retention and hyperglycemia. Lidocaine: Reduce bolus dose (e.g., 0.5-1 mg/kg) and infusion rate (e.g., 1-2 mg/min); monitor for neurotoxicity and cardiac depression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DECADRON W/ XYLOCAINE (DECADRON W/ XYLOCAINE).
| Breastfeeding | Dexamethasone: Excreted in breast milk; M/P ratio unknown. Lidocaine: M/P ratio 0.4-0.6, minimal infant exposure. Use caution with high-dose or prolonged therapy. Monitor infant for adrenal suppression (dexamethasone) or CNS effects (lidocaine). |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.3) with systemic corticosteroids. Second/third trimesters: Possible fetal adrenal suppression, intrauterine growth restriction, and premature rupture of membranes. Lidocaine crosses placenta but not teratogenic at clinical doses. |
■ FDA Black Box Warning
Not for intravenous or spinal administration. Lidocaine formulations containing preservatives (e.g., methylparaben) are contraindicated for epidural or intrathecal use due to risk of neurotoxicity.
| Serious Effects |
Systemic fungal infections, hypersensitivity to corticosteroids or lidocaine/amide-type anesthetics, severe hypotension, heart block, or concurrent use of class I antiarrhythmics.
| Precautions | Avoid inadvertent intravascular injection (may cause cardiac arrest). Use caution in patients with hepatic impairment, severe hypertension, or diabetes. Prolonged use may lead to adrenal suppression, Cushing's syndrome, or osteoporosis. |
Loading safety data…
| Fetal Monitoring | Maternal: Blood glucose, blood pressure, signs of infection, bone density with prolonged use. Fetal/neonatal: Serial ultrasound for growth restriction; monitor for neonatal hypoglycemia, adrenal insufficiency, and cardiac arrhythmias if lidocaine used near term. |
| Fertility Effects | Dexamethasone may suppress endogenous steroid production, potentially affecting menstrual regularity and ovulation. Lidocaine has no known effect on fertility. High-dose or chronic use may impair gamete function. |